Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Immunosurveillance in clinical cancer management
Guido Guido Kroemer, Timothy A. Chan, Alexander M.M. Eggermont, Lorenzo Galluzzi (2023). Immunosurveillance in clinical cancer management. , 74(2), DOI: https://doi.org/10.3322/caac.21818.
Article207 days agoAnticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
Dalil Hannani, Marie Vétizou, David Enot, Sylvie Rusakiewicz, Nathalie Chaput, David Klatzmann, Mélanie Desbois, Nicolas Jacquelot, Nadège Vimond, Salem Chouaı̈b, Christine Mateus, James P. Allison, Antoni Ribas, Jedd D. Wolchok, Jianda Yuan, Phillip Wong, Michael A. Postow, Andrzej Maćkiewicz, Jacek Mackiewicz, Dirk Schadendorff, Dirk Jaeger, Alan J. Korman, Keith S. Bahjat, Michele Maio, Luana Calabrò, Michele W.L. Teng, Mark J. Smyth, Alexander M.M. Eggermont, Caroline Robert, Guido Guido Kroemer, Laurence Zitvogel (2015). Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. , 25(2), DOI: https://doi.org/10.1038/cr.2015.3.
Article207 days agoDoubling the blockade for melanoma immunotherapy
Lorenzo Galluzzi, Alexander M.M. Eggermont, Guido Guido Kroemer (2015). Doubling the blockade for melanoma immunotherapy. , 5(1), DOI: https://doi.org/10.1080/2162402x.2015.1106127.
Article207 days agoModes of action of ipilimumab and biomarkers of resistance to therapy in patients
Dalil Hannani, Marie Vétizou, David Enot, Sylvie Rusakiewicz, Sophie Viaud, D. Klazmann, Nathalie Chaput, Alexander M.M. Eggermont, Guido Guido Kroemer, Caroline Robert, Laurence Zitvogel (2013). Modes of action of ipilimumab and biomarkers of resistance to therapy in patients. , 140(12), DOI: https://doi.org/10.1016/j.annder.2013.09.653.
Article207 days ago1095P Pembrolizumab versus placebo after a complete resection of high-risk stage III melanoma: 7-year results of the EORTC 1325-MG/Keynote-054 double-blind phase III trial
Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, Mario Mandalà, G.V. Long, V.G. Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Muhammad A. Khattak, M.S. Carlino, Shahneen Sandhu, Susana Puig, Paolo A. Ascierto, P. Lorigan, D. Grebennik, C. Krepler, Sandrine Marréaud, Stefan Suciu, C. Robert (2024). 1095P Pembrolizumab versus placebo after a complete resection of high-risk stage III melanoma: 7-year results of the EORTC 1325-MG/Keynote-054 double-blind phase III trial. , 35, DOI: https://doi.org/10.1016/j.annonc.2024.08.1163.
Article196 days ago